BioSpace News Archive

Samsung Bioepis Co., Ltd. announced that the U.S. Food and Drug Administration has approved a 420 mg multi-dose vial of ONTRUZANT®, a biosimilar referencing HERCEPTIN®

Shenzhen Chipscreen Biosciences Co., Ltd. announced that the company’s application for Investigational New Drug of CS12192 has been accepted by Center for Drug Evaluation, National Medical Products Administration of China.

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today reported financial results for the fourth quarter and full year ended December 31, 2019, while providing a corporate update.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that Walter Klemp, Chairman and Chief Executive Officer, will present at the Life Sciences Investor Forum being held online at LifeSciencesInvestorForum.com on March 26th.

Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today it has filed a new provisional patent application with the U.S. Patent and Trademark Office entitled, “Lung Endothelial Binding Agents And Methods Of Use” to protect new drug candidates that reduce lung inflammation.

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), announced today the allowance by the United States Patent and Trademark Office on March 5, 2020, of a US patent application claiming an integrated and decomposable micro apparatus that can be used for site-specific delivery of a drug, a medical kit

GE Healthcare and Ford collaborate to accelerate and scale ventilator production, supporting clinicians in the treatment of COVID-19 patients

Paul Bisaro and Gail Naughton, Ph.D., Appointed as Independent Directors –

Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease (SCD) treatment, announced today several steps it has taken in response to the Coronavirus (COVID-19) pandemic.

Eli Lilly and Company (NYSE: LLY) today is providing updates related to insulin supply and affordability: As we announced on March 3 , Lilly does not currently anticipate shortages for any of our medicines, including all forms of insuli